APA (7th ed.) Citation

Kipps, T. J., Eradat, H., Grosicki, S., Catalano, J., Cosolo, W., Dyagil, I. S., . . . Pylypenko, H. (2015). A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leukemia & Lymphoma, 56(10), 2826. https://doi.org/10.3109/10428194.2015.1030638

Chicago Style (17th ed.) Citation

Kipps, Thomas J., et al. "A Phase 2 Study of the BH3 Mimetic BCL2 Inhibitor Navitoclax (ABT-263) with or Without Rituximab, in Previously Untreated B-cell Chronic Lymphocytic Leukemia." Leukemia & Lymphoma 56, no. 10 (2015): 2826. https://doi.org/10.3109/10428194.2015.1030638.

MLA (9th ed.) Citation

Kipps, Thomas J., et al. "A Phase 2 Study of the BH3 Mimetic BCL2 Inhibitor Navitoclax (ABT-263) with or Without Rituximab, in Previously Untreated B-cell Chronic Lymphocytic Leukemia." Leukemia & Lymphoma, vol. 56, no. 10, 2015, p. 2826, https://doi.org/10.3109/10428194.2015.1030638.